PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $9.46 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $9.36, a 37.18% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $14.90, a 50.37% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $30.02, a 43.50% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $53.13, a 61.34% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $14.26, a 50.30% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $28.69, a 49.20% decline from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $56.48, a 70.48% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $33.13, a 19.52% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $9.46 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $9.36 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $14.26 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $14.26 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $14.26 10-Q · filed 2025-08-04 | ||||
| 2025-03-31 | $14.90 10-Q · filed 2025-05-08 | ||||
| 2024-12-31 | $28.69 10-K · filed 2025-02-27 | ||||
| 2024-09-30 | $29.45 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $29.45 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | $30.02 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | $56.48 10-K · filed 2024-02-22 | ||||
| 2023-09-30 | $56.94 10-Q · filed 2023-11-02 | ||||
| 2023-06-30 | $55.45 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | $53.13 10-Q · filed 2023-05-04 | ||||
| 2022-12-31 | $33.13 10-K · filed 2023-02-28 | ||||
| 2022-09-30 | $31.97 10-Q · filed 2022-11-03 | ||||
| 2022-06-30 | $32.30 10-Q · filed 2022-08-08 | ||||
| 2022-03-31 | $32.93 10-Q · filed 2022-05-05 | ||||
| 2021-12-31 | $27.72 10-K · filed 2022-02-25 | ||||
| 2021-09-30 | $25.19 10-Q · filed 2021-11-04 | ||||
| 2021-06-30 | $22.95 10-Q · filed 2021-08-05 | ||||
| 2021-03-31 | $22.39 10-Q · filed 2021-05-11 | ||||
| 2021-02-12 | $22.85 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $11.81 10-K · filed 2021-02-26 | ||||
| 2020-09-30 | $11.94 10-Q · filed 2020-11-04 | ||||
| 2020-06-30 | $11.87 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | $12.00 10-Q · filed 2020-05-06 | ||||
| 2019-12-31 | $12.16 10-K · filed 2020-03-03 | ||||
| 2019-09-30 | $12.24 10-Q · filed 2019-11-05 | ||||
| 2019-06-30 | $12.85 10-Q · filed 2019-08-06 | ||||
| 2019-03-31 | $13.44 10-Q · filed 2019-05-07 | ||||
| 2018-12-31 | $20.20 10-K · filed 2019-03-15 | ||||
| 2018-09-30 | $20.39 10-Q · filed 2018-11-06 | ||||
| 2018-06-30 | $20.39 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |